FATE
FATE THERAPEUTICS INC
+0.06 (+2.25%)2.50USD537K成交股數299M市值–本益比(近四季)46.1股價營收比+9.2%營收年增(近四季)2026-11-12下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 2.1M+9% | 1.3M-20% | 1.4M-55% | 1.7M-74% | 1.9M-1% | 1.6M-3% | 3.1M+58% | 6.8M+626% | 1.9M | 1.7M | 1.9M | 933K |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 24.4M | 24.7M | 25.4M | 25.8M | 27.4M | 29.1M | 34.7M | 34.6M | 32.1M | 31.8M | 34.3M | 40.9M |
| 銷售管理費用 | 8.8M | 9.6M | 10.7M | 10.6M | 11.4M | 13.8M | 20.8M | 17.3M | 20.9M | 17.9M | 18.9M | 22.6M |
| 營業利益 | −31.1M-16% | −33.0M-20% | −34.7M-34% | −34.7M-23% | −37.0M-28% | −41.3M-14% | −52.4M+2% | −45.1M-28% | −51.1M | −48.1M | −51.3M | −62.6M |
| 營業利益率 | -1,495.4% | -2,540.4% | -2,536.2% | -1,995.1% | -1,938.5% | -2,534.1% | -1,703.9% | -665.7% | -2,652.9% | -2,868.4% | -2,637.8% | -6,705.8% |
| 稅後淨利 | −30.2M-11% | −31.2M-17% | −32.4M-32% | −32.3M-16% | −34.1M-29% | −37.6M-15% | −47.7M+6% | −38.4M-27% | −48.0M | −44.1M | −45.2M | −52.8M |
| 淨利率 | -1,448.6% | -2,402.8% | -2,364.8% | -1,852.4% | -1,786.6% | -2,309.5% | -1,551.0% | -567.4% | -2,493.7% | -2,632.6% | -2,323.6% | -5,654.3% |
| 稀釋 EPS | -0.25-14% | -0.26-19% | -0.27-32% | -0.27-18% | -0.29-38% | -0.32-29% | -0.40-13% | -0.33-39% | -0.47 | -0.45 | -0.46 | -0.54 |
| 稀釋股數 | 120M | 120M | 119M | 119M | 119M | 118M | 118M | 117M | 101M | 98.4M | 98.6M | 98.4M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 32.4M | 39.6M | 46.6M | 40.6M | 41.2M | 44.9M | 37.9M | 36.9M | 121M | 41.9M | 33.3M | 46.8M |
| 應收帳款 | 703K | 704K | 916K | 682K | 1.4M | 2.4M | 4.1M | 1.0M | 858K | 1.8M | 1.5M | 2.8M |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 260M | 285M | 319M | 344M | 372M | 399M | 495M | 529M | 570M | 506M | 544M | 585M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 股東權益 | 153M | 180M | 207M | 234M | 261M | 288M | 362M | 397M | 426M | 368M | 403M | 438M |
| 負債比 | – | – | – | – | – | – | – | – | – | – | – | – |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | −23.4M | −30.8M-9% | – | – | – | −33.8M | – | – | −33.4M | – | – | – |
| 資本支出 | – | 239K | – | – | – | 1.2M | – | – | 86K | – | – | – |
| 自由現金流 | – | −31.1M-11% | – | – | – | −35.0M | – | – | −33.4M | – | – | – |
| 折舊攤銷 | – | 2.9M | – | – | – | 3.3M | – | – | 4.8M | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -2,391.1% | – | – | – | -2,148.9% | – | – | -1,736.9% | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 6.6M | -51.2% | −136M | -2,051.1% | -1.15 | −112M |
| FY2024 | 13.6M | -78.5% | −186M | -1,366.5% | -1.64 | −124M |
| FY2023 | 63.5M | -34.0% | −161M | -253.3% | -1.64 | −138M |
| FY2022 | 96.3M | +72.4% | −282M | -292.5% | -2.91 | −284M |
| FY2021 | 55.8M | +77.7% | −212M | -379.9% | -2.24 | −214M |
| FY2020 | 31.4M | +194.3% | −173M | -551.6% | -2.10 | −44.2M |
| FY2019 | 10.7M | +125.3% | −98.1M | -919.0% | -1.44 | −90.6M |
| FY2018 | 4.7M | – | −66.6M | -1,405.0% | -1.19 | −41.0M |